Vicuron Pharmaceuticals Announces Departure From Board of Directors of Ubaldo Livolsi and Francesco Parenti
July 02 2004 - 7:30AM
PR Newswire (US)
Vicuron Pharmaceuticals Announces Departure From Board of Directors
of Ubaldo Livolsi and Francesco Parenti KING OF PRUSSIA, Pa., July
2 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (Nasdaq:
MICU; Nuovo Mercato: MICU), today announced the resignation of
Ubaldo Livolsi, Ph.D., and retirement of Francesco Parenti, Ph.D.,
from the company's board of directors. "We are grateful to Drs.
Livolsi and Parenti for their work and contributions, particularly
over the last year in helping to guide the successful merger
between Versicor and BioSearch Italia," said George F. Horner III,
Vicuron's president and chief executive officer. "As true pioneers
in the field, their knowledge, experience and insight were
instrumental in the building of our company." About Vicuron Vicuron
Pharmaceuticals is a biopharmaceutical company focused on
discovering, developing, manufacturing and commercializing vital
medicine for seriously ill patients in North America and major
countries in Europe. The company's lead product, anidulafungin is
under review by the U.S. Food and Drug Administration. The
company's other lead product, dalbavancin, a novel intravenous
antibiotic for the treatment of serious Gram-positive infections,
is in Phase III clinical trials. The company's versatile research
engine integrates industry-leading expertise in functional
genomics, natural products discovery, mechanism-based drug design
and combinatorial and medicinal chemistry. These approaches are
yielding promising novel and next-generation compounds, many of
which are in the later stages of preclinical development. In
addition, the company has research and development collaborations
with leading pharmaceutical companies, such as Pfizer and Novartis.
Forward-Looking Statements This news release contains
forward-looking statements that predict or describe future events
or trends. The matters described in these forward- looking
statements are subject to known and unknown risks, uncertainties
and other unpredictable factors, many of which are beyond Vicuron's
control. Vicuron faces many risks that could cause its actual
performance to differ materially from the results predicted by its
forward-looking statements, including the possibilities that
clinical trials and the results thereof might be delayed, that the
timing of the filing of any new drug application might be delayed,
that subsequent clinical trials might indicate that a product
candidate is unsafe or ineffective, that any filed new drug
application may not be approved, that ongoing proprietary and
collaborative research might not occur or yield useful results,
that a third party may not be willing to license our product
candidates on terms acceptable to us or at all, that competitors
might develop superior substitutes for their products or market
them more effectively, that a sales force may not be developed as
contemplated and that one or more of its product candidates may not
be commercialized successfully. The reports that Vicuron files with
the U.S. Securities and Exchange Commission contain a fuller
description of these and many other risks to which Vicuron is
subject. Because of those risks, Vicuron's actual results,
performance or achievements may differ materially from the results,
performance or achievements contemplated by its forward-looking
statement. The information set forth in this news release
represents management's current expectations and intentions.
Vicuron assumes no responsibility to issue updates to the
forward-looking matters discussed in this news release. DATASOURCE:
Vicuron Pharmaceuticals Inc. CONTACT: Dov A. Goldstein, M.D. of
Vicuron Pharmaceuticals Inc., +1-610-205-2312, or ; or Hala Bashir
of WeissCom Partners, +1-212-204-2080, or , for Vicuron
Pharmaceuticals Inc.; or Aline Schimmel of Burns McClellan,
+1-212-213-0006, or , for Vicuron Pharmaceuticals Inc. Web site:
http://www.vicuron.com/
Copyright